



## Lipids - one huge step for healthcare?

### PROGRAMME

#### Tuesday 5 July

TIME	SESSION DUR MINS	TOPIC	SPEAKER	LOCATION
18:00 – 22:00	240	EXHIBITION BUILD		Oculus foyer

#### Wednesday 6 July

TIME	SESSION DUR MINS	TOPIC	SPEAKER	LOCATION
07:00 - 09:00		Breakfast ( <i>Bluebell House residential guests only</i> )		Rootes Building - 1st floor restaurant
09:00		Registration opens		Oculus foyer
09:00 - 11:00	120	<b>HEART UK MS&amp;R Committee meeting</b>	Chair - Dr Handrean SORAN	Oculus room no tbc
11:00 - 11:15		break		
11:15 - 12:30	75	<b>Lipid Interest group meeting</b>	Chair - Alison POTTLE	Oculus room no tbc
11:00 - 12:30	60	Registration   Networking   Exhibition		Oculus foyer
11:45 - 12:30	45	Lunch		Oculus foyer
12:30 - 12:40	10	<b>Chairman's Welcome</b> Celebrating 20 years since the BHA/FHA merger	<b>Dr Peter GREEN</b>	Oculus LT 1.05 - 1st floor
		<b>SESSION ONE</b>		
		Co-chairs: <b>Peter Penson + Michaela Nuttall</b>		
		<b>Plenary speaker</b>		
12:40 - 13:05	25	<b>Pharmacists view and new treatments</b>	<b>Dr Rani KHTAB</b> (Leeds)	Oculus LT 1.05 - 1st floor
13:05 - 13:15	10	Discussion		
		<b>Plenary speaker</b>		
13:15 - 13:40	25	<b>CVD Risk and gender- reassignment</b>	<b>Dr Devi NAIR</b> (London)	Oculus LT 1.05 - 1st floor
13:40 - 13:50	10	Discussion		
13:50 - 14:20	30	Refreshments   Networking   Exhibition		Oculus foyer

		<b>SESSION TWO - Fats v Carbs in Lipid Management - the Controversy</b>		
		<b>Chair: Alan Flanagan</b> <b>Primary speaker</b>		
		<b>Evidence for fats and carbs</b> In contrast to controversy, there is now clear consensus on the amount and quality of dietary fat and carbohydrate for the management of blood lipids. Controversy has arisen over the effects of extreme diets which exclude one of these macro-nutrients. While there is consistent evidence that this dietary approach can help to promote weight loss and improve weight-related biomarkers of cardiovascular risk, an important and outstanding question is whether high fat, low carb diets carry potential for adverse effects on blood cholesterol?		
14:20 - 15:20	60		<b>Prof Bruce GRIFFIN</b> (Surrey)	Oculus LT 1.05 - 1st floor
15:20 - 15:30	10	Discussion		
15:30 - 16:00	30	Refreshments   Networking   Exhibition		Oculus foyer
		<b>SESSION THREE - sponsored symposia</b>		
		<b>Symposia session 1</b>		
16:00 - 16:40	40	<b>Sponsored by Sanofi</b>		Oculus LT 0.03 - ground floor
16:40 - 16:50	10	Changeover		
		<b>Symposia session 2</b>		
		<b>What more can we do to optimise lipid management in your patients experiencing statin intolerance</b> This sponsored promotional symposium is organised by Daiichi Sankyo UK. The speaker faculty will discuss the clinical management of patients with elevated cholesterol intolerant to statin therapy.	<b>Dr Yassir JAVAID</b> , Cardiology GPSI and Clinical lead for Cardiology East Midlands Clinical Network  <b>Professor Sudarshan RAMACHANDRAN</b> , Consultant Chemical Pathologist, University Hospitals Birmingham / University Hospitals of North Midlands	
16:50 - 17:30	40	<b>Sponsored by Daiichi-Sankyo</b>		Oculus LT 0.03 - ground floor
17:30 - 18:30	60	Break - check into accommodation		
17:30 - 18:00	30	<b>HEART UK AGM</b>	Chair - Jules Payne	Oculus LT 0.03 - ground floor
18:30 - 19:10	40	<b>FH nurses informal networking session</b>	Hosted by: Lisa Gritzmacher	Oculus - 1st floor landing
18:30 - 21:30	180	<b>Welcome reception and buffet reception</b>		Oculus foyer
19:00:00		Chairman's welcome		
		Presentation of the Rianna Wingett award	<b>Pete to present award or Alan if he attends</b>	
21:30:00		Evening ends		

## Thursday 7 July

TIME	SESSION DUR MINS	TOPIC	SPEAKER	LOCATION
07:00 - 09:00		Breakfast ( <i>Bluebell House residential guests only</i> )		Rootes Building - 1st floor restaurant
08:00 - 09:00		<b>Healthcare committee meeting</b>	Hosted by: Michaela Nuttall	Oculus mtg room no tbc
08:30		Registration opens		Oculus foyer
08:30 - 09:20	50	Refreshments   Networking   Exhibition		Oculus foyer
09:20 - 09:25	5	<b>Opening remarks</b>	<b>Dr Nigel CAPPS</b>	Oculus LT 1.05 - 1st floor
	70	<b>SESSION FOUR</b>		
		Co-chairs: <b>Sara Jenks + Kate Shipman</b>		

09:25 - 09:50	25	<b>Plenary speaker</b> <b>Statin myopathy and myotitis</b>	<b>Dr Harsha GUNAWARDENA</b> (Southmead)	Oculus LT 1.05 - 1st floor
09:50 - 10:00	10	Discussion		
10:00 - 10:25	25	<b>Plenary speaker</b> <b>The role of non-invasive CT coronary angiography in the Lipid Clinic</b> An overview of the past, current and future CT technologies that non-invasively assess for coronary artery disease and how they can impact the clinical management of high risk asymptomatic patients with lipid disorders.	<b>Dr Jonathan C. L. RODRIGUES</b> (Bath)	Oculus LT 1.05 - 1st floor
10:25 - 10:35	10	Discussion		
10:35 - 11:05	30	Refreshments   Networking   Exhibition		
	70	<b>SESSION FIVE</b>		
11:05 - 12:15	70	<b>Lipids - Devolution Differences</b> A discussion of the varied approaches to diagnosis and management in different parts of the United Kingdom Hear representative views (10-15 mins each) from England, N Ireland, Scotland and Wales.C63 Followed by lively discussion – audience experience and views invited	Facilitator/Chair - <b>Ian MCDOWELL</b> England   <b>Kate SHIPMAN</b> (Chichester) N Ireland   <b>Paul HAMILTON</b> (Belfast) Scotland   <b>Sara JENKS</b> (NHS Lothian) Wales   <b>Yee Ping TEOH</b> (Wales)	Oculus LT 1.05 - 1st floor
12:15 - 13:30	75	Lunch   Networking   Exhibition		Oculus foyer
12:15 - 13:30	75	<b>Simon Broome committee meeting</b>	Hosted by: Nigel Capps	Oculus mtg room no tbc
12:30 - 12:50	20	<b>Meet the Expert Taster session 1:</b> <b>Pill Swallowing</b> Discussing the barriers to adherence with lipid-lowering medicines.	<b>Dr Alice MCCLOSKEY</b> (Liverpool, UK)	Oculus mtg space tbc
12:50 - 12:55	5	Break		
12:55 - 13:15	20	<b>Meet the Expert Taster session 2:</b> <b>Careers in Lipidology</b> Nurses career path and credentialling for nurses	<b>Ms Lisa GRITZMACHER</b> <b>Prof Elizabeth HUGHES</b> <b>Dr Peter PENSON</b>	Oculus mtg space tbc
	75	<b>SESSION SIX - Lp(a)</b> Co-chairs: <b>Mike Khan</b> + <b>Dermot Neely</b>		
13:30 - 14:00	30	<b>Plenary speaker</b> <b>Lp(a) scientific update / prevalence</b>	<b>Prof Sam TSIMIKAS</b> (San Diego, USA)	Oculus LT 1.05 - 1st floor
14:00 - 14:10	10	Discussion		
14:10 - 14:35	25	<b>Plenary speaker</b> <b>State of the nation - UK view on Lp(a)</b> Presentation of the findings of a recent survey performed by HEART UK of lipid clinics and clinical biochemistry laboratories to understand the availability, methodology and application of lipoprotein(a) measurement in the UK.	<b>Dr Jai CEGLA</b> (London, UK)	Oculus LT 1.05 - 1st floor
14:35 - 14:45	10	Discussion		
14:45 - 15:30	45	Refreshments   Networking   Exhibition		Oculus foyer
	75	<b>SESSION SEVEN</b> <b>Abstracts of free communications   Medical &amp; Scientific</b> Oculus LT 1.05 - 1st floor	<b>SESSION SEVEN</b> <b>Abstracts of free communications   Primary &amp; Healthcare</b> Oculus LT 0.03 - ground floor	
		Co-chairs: <b>Gordon Ferns</b> + <b>Ben Jones</b> (TBC)	Co-chairs: <b>Elizabeth Hughes</b> + <b>Alison Pottle</b>	

15:30 - 15:40	10	<b>FC 1</b> Lomitapide in the long-term real-world management of HoFH – effectiveness, tolerability, and hepatic safety from the Pan-European study <a href="#">Jai Cegla</a> (London, UK)	<b>FC 6</b> Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): a study comparing FH individuals in UK primary care and the UK Simon Broome register linked with secondary care records <a href="#">Barbara Iyen</a> (Nottingham, UK)	
15:40 - 15:45	5	Discussion	Discussion	
15:45 - 15:55	10	<b>FC 2</b> Posttranscriptional regulation of the LDL Receptor in humans by the U2-spliceosome and its interactors <a href="#">M Futema</a> (London, UK)	<b>FC 7</b> Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank <a href="#">Jasmine Gratton</a> (London, UK)	
15:00 - 16:00	5	Discussion	Discussion	
16:00 - 16:10	10	<b>FC 3</b> Machine learning to optimise cholesterol-lowering therapy: proof-of-concept study in UK primary care <a href="#">Andrew J Krentz</a> (London, UK)	<b>FC 8</b> Familial Hypercholesterolaemia - a targeted Next Generation Sequencing panel and retrospective analysis of patients with no previously identified pathogenic variant <a href="#">Eloise Willis</a> (Cardiff, UK)	
16:10 - 16:15	5	Discussion	Discussion	
16:15 - 16:25	10	<b>FC 4</b> Lipoprotein apheresis reduces SARS-CoV-2 S protein antibody levels in patients with familial hypercholesterolaemia after vaccination with BNT162b2 <a href="#">Jai Cegla</a> (London, UK)	<b>FC 9</b> The potential cost-effectiveness of screening algorithms for familial hypercholesterolemia in primary care <a href="#">Steve E Humphries</a> (London, UK)	
16:25 - 16:30	5	Discussion	Discussion	
16:30 - 16:40	10	<b>FC 5</b> Low-density lipoprotein receptor-negative compound heterozygous familial hypercholesterolaemia: case study with follow-up over 23 years <a href="#">Charles van Heyningen</a> (Liverpool, UK)	<b>FC 10</b> How should high cholesterol, mutation negative children, identified through the child-parent screening project be managed? <a href="#">Lorraine Priestley-Barnham</a> (Harefield, UK)	
16:40 - 16:45	5	Discussion	Discussion	
16:45 - 17:05	20	Refreshments   Networking   Exhibition		Oculus foyer
	60	<b>SESSION EIGHT</b>		
		Chair: <a href="#">Handrean Soran</a>		
17:05 - 18:05	60	<b>Keynote Myant lecture:</b> Severe familial hypercholesterolaemia – from a lethal disorder in childhood to a manageable dyslipidaemia today Overcoming the challenges of severe FH has been a long and difficult journey, but with the treatment options now available, the future for severe FH looks bright.	<a href="#">Prof Frederick RAAL</a> (Johannesburg, South Africa)	Oculus LT 1.05 - 1st floor
18:05 - 18:10	5	Day two closing remarks		
19:00 - 19:30	30	Pre dinner drinks reception		Chancellors - Rootes Building
19:30 - 23:30		Conference dinner and disco		Chancellors - Rootes Building



## Friday 8 July

TIME	SESSION	TOPIC	SPEAKER	LOCATION
	DUR MINS			

07:00 - 09:00		Breakfast (Bluebell House residential guests only)		Rootes Building - 1st floor restaurant
08:30		Registration opens		Oculus foyer
08:00 - 09:00		<b>Apheresis Working Group committee meeting</b>	Chaired by: Dev Datta	Oculus room no tbc
08:30 - 09:30	60	Refreshments   Networking   Exhibition		Oculus foyer
09:00 - 10:00	60	<b>Spotlight on posters session</b>		Oculus first floor landng
		<b>Moderated</b>		
		Judges   <a href="#">Frederick Raal</a> , <a href="#">Alan Rees</a> , <a href="#">Alison Pottle</a> , <a href="#">Jai Cegla</a>		
	1	<b>Development of a novel secondary care lipid e-referral pathway within Gloucestershire Hospitals NHS Foundation Trust</b> <a href="#">Kylie Beale</a> (Gloucester, UK)		
	2	<b>Assessment of GENinCode in the Diagnosis of Patients with Suspected Familial Hypercholesterolaemia</b> <a href="#">Peter E Carey</a> (Sunderland, UK)		
	3	<b>A primary Care based Familial Hypercholesterolaemia screening service in Guernsey, from concept to delivery</b> <a href="#">Matt Dorrian</a> (Guernsey, UK)		
	4	<b>Effect of SLCO1B1 genotypes on statin intolerance and response</b> <a href="#">Rahul Ghelani</a> (Harefield, UK)		
	5	<b>Low carbohydrate ketogenic diets as a cause of markedly elevated low-density lipoprotein cholesterol</b> <a href="#">Laura Hancox</a> (Bristol, UK)		
	6	<b>I used to dream that my cholesterol could be in single figures, and now it is!!!</b> <a href="#">Alison Pottle</a> (London, UK)		
	7	<b>The effect of adjusting LDL-cholesterol for Lipoprotein(a)-cholesterol on the diagnosis of Familial Hypercholesterolaemia</b> <a href="#">Darmiga Thayabaran</a> (London, UK)		
	8	<b>How many homozygous Familial Hypercholesterolaemia (FH) patients are there likely to be in the UK? : The FH phenotype caused the APOB p.(Arg3527Trp) variant in a South Asian family</b> <a href="#">Inessa Tracey</a> (West Bromwich, UK)		
	9	<b>An outreaching lipid clinic model supporting PCSK9i uptake and lipid optimisation in secondary prevention across primary/secondary care interface</b> <a href="#">Catherine Tucker</a> (North Sheilds, UK)		
	10	<b>An investigation into any correlation between Single Nucleotide Polymorphism (SNP) score and Welsh score in Familial Hypercholesterolaemia patients and those with polygenic hypercholesterolaemia</b> <a href="#">Jillian Webster</a> (Huddersfield, UK)		
		<b>Unmoderated</b>		
	11	<b>Systematic vs opportunistic identification of familial hypercholesterolaemia in Malaysian primary care: a before and after study</b> <a href="#">Hasidah Abdul-Hamid</a> (Nottingham, UK)		
	12	<b>In An Ever-Changing World, Communication is Key</b> <a href="#">Charis Browne</a> (London, UK)		
	13	<b>Exploring the lived experience of being diagnosed with genetically confirmed familial hypercholesterolaemia in childhood</b> <a href="#">Charis Browne</a> (London, UK)		
	14	<b>FH Case Finding: A Multidisciplinary Review Post Cardiac intervention Patients in a NHS Trust between June 2019 and June 2021</b> <a href="#">Eimear Connell</a> (Sunderland, UK)		
	15	<b>How prepared are hairdressing salons and GP practices for working in partnership to promote the uptake of cardiovascular disease screening among women living in London's deprived and ethnically dense communities?</b> <a href="#">Tethi Patel</a> (London, UK)		

	16	An ounce of prevention is worth a pound of cure', Harefield Familial Hypercholesterolaemia Service - Past Present and Future <a href="#">Lorraine Priestley-Barnham</a> (Manchester, UK)	
	17	A pharmacist-led remote model for identification and optimisation of Familial Hypercholesterolaemia patients in primary care <a href="#">Charlotte Scott</a> (Tyne & Wear, UK)	
	18	Lipoprotein Apheresis: Delivering and Sustaining a Service Throughout the COVID-19 Global Pandemic <a href="#">Jo Senior</a> (London, UK)	
	19	Diagnosing Familial Hypercholesterolaemia (FH) as an additional finding from taking part in the 100,000 genomes project, the Wessex experience <a href="#">Catherine Sherman</a> (Southampton, UK)	
	20	Cascade screening for lipoprotein (a); controversies and guidance <a href="#">Kate Shipman</a> (London, UK)	
	21	NHS North Thames Genomic Medicine Service Alliance (NHS NTGMSA) Pilot: Implementing UCLPartners Proactive Care Framework for Familial Hypercholesterolaemia Screening and Cascade Testing in Primary Care <a href="#">Dominic Studart</a> (London, UK)	
10:00 - 10:10	10	Comfort break	
	90	<b>SESSION NINE - sponsored symposia</b>	
10:10 - 10:50	40	Symposia session 3 Sponsored by Amarin	Oculus LT 0.03 - ground floor
10:50 - 11:00	10	Changeover	
11:00 - 11:40	40	Symposia session 4 Sponsored by Amgen	Oculus LT 0.03 - ground floor
11:40 - 12:10	30	Refreshments   Networking   Exhibition	Oculus foyer
		<b>SESSION TEN - Clinical Lipidology Live</b>	
12:10 - 13:10	60	Live patient case studies and discussion	Facilitator: <a href="#">Dev DATTA</a> + <a href="#">Michaela NUTTALL</a>
13:10 - 13:20	10	Closing remarks - 20 years on since the BHA/FHA merger - is it one huge step for healthcare?	<a href="#">Dr Pete GREEN</a> (chair - HEART UK)